Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.

Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.